<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2024//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_240101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">37968601</PMID><DateCompleted><Year>2023</Year><Month>11</Month><Day>27</Day></DateCompleted><DateRevised><Year>2023</Year><Month>11</Month><Day>27</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">1471-2334</ISSN><JournalIssue CitedMedium="Internet"><Volume>23</Volume><Issue>1</Issue><PubDate><Year>2023</Year><Month>Nov</Month><Day>15</Day></PubDate></JournalIssue><Title>BMC infectious diseases</Title><ISOAbbreviation>BMC Infect Dis</ISOAbbreviation></Journal><ArticleTitle>Epstein-Barr virus reactivation is not causative for post-COVID-19-syndrome in individuals with asymptomatic or mild SARS-CoV-2 disease course.</ArticleTitle><Pagination><StartPage>800</StartPage><MedlinePgn>800</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">800</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1186/s12879-023-08820-w</ELocationID><Abstract><AbstractText Label="PURPOSE" NlmCategory="OBJECTIVE">Post-COVID-19-Syndrome (PCS) frequently occurs after an infection with severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2). However, the understanding of causative mechanisms is still limited. Aim of this study was to determine the PCS rate among SARS-CoV-2 seropositive blood donors as representatives of supposedly healthy adults, who had experienced an asymptomatic or mild COVID-19 disease course, and to examine whether Epstein-Barr virus (EBV) is reactivated in individuals reporting PCS.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">The PCS rate was determined using questionnaires that included questions about infection and persistent symptoms. Pre-pandemic blood samples and samples collected at regular, pre-defined times after a SARS-CoV-2 infection were analysed for neopterin, a marker for antiviral immune responses, by an enzyme-linked immunosorbent assay (ELISA). Additionally, we determined the rate of SARS-CoV-2 anti-N total antibodies using an electrochemiluminescence immunoassay (ECLIA). Furthermore, quantitative real-time polymerase chain reaction (qPCR) to detect EBV DNA and ECLIA screening for EBV viral capsid-antigen (VCA) IgM, IgG and EBV nuclear antigen 1 (EBNA) IgG were performed.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Our data reveal that 18% of all infections result in PCS, with symptoms lasting for up to one year. In individuals reporting PCS, no elevated levels of neopterin were detected, indicating no persisting pro-inflammatory, antiviral immune response. SARS-CoV-2 antibody levels were declining in all participants in comparable manner over time, pointing to a successful virus clearance. In individuals with PCS, no EBV DNA could be detected. Furthermore, no differences in EBV specific antibody levels could be shown in PCS groups compared to non-PCS groups.</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">Our data suggest that PCS in per se healthy, immunocompetent adults cannot be ascribed to a reactivation of EBV.</AbstractText><CopyrightInformation>&#xa9; 2023. The Author(s).</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y" EqualContrib="Y"><LastName>Hoeggerl</LastName><ForeName>Alexandra Domnica</ForeName><Initials>AD</Initials><AffiliationInfo><Affiliation>Department of Transfusion Medicine, University Hospital of Salzburg (SALK), Paracelsus Medical University (PMU) Salzburg, M&#xfc;llner-Hauptstra&#xdf;e 48, Salzburg, 5020, Austria.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y" EqualContrib="Y"><LastName>Nunhofer</LastName><ForeName>Verena</ForeName><Initials>V</Initials><AffiliationInfo><Affiliation>Department of Transfusion Medicine, University Hospital of Salzburg (SALK), Paracelsus Medical University (PMU) Salzburg, M&#xfc;llner-Hauptstra&#xdf;e 48, Salzburg, 5020, Austria.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lauth</LastName><ForeName>Wanda</ForeName><Initials>W</Initials><AffiliationInfo><Affiliation>Team Biostatistics and Big Medical Data, IDA Lab Salzburg, PMU Salzburg, Strubergasse 16, Salzburg, 5020, Austria.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Research and Innovation Management, PMU Salzburg, Strubergasse 16, Salzburg, 5020, Austria.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Badstuber</LastName><ForeName>Natalie</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Department of Psychological Assessment, Institute of Psychology, Paris-Lodron-University of Salzburg, Salzburg, Austria.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Held</LastName><ForeName>Nina</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Department of Transfusion Medicine, University Hospital of Salzburg (SALK), Paracelsus Medical University (PMU) Salzburg, M&#xfc;llner-Hauptstra&#xdf;e 48, Salzburg, 5020, Austria.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zimmermann</LastName><ForeName>Georg</ForeName><Initials>G</Initials><Identifier Source="ORCID">0000-0002-8282-1034</Identifier><AffiliationInfo><Affiliation>Team Biostatistics and Big Medical Data, IDA Lab Salzburg, PMU Salzburg, Strubergasse 16, Salzburg, 5020, Austria.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Research and Innovation Management, PMU Salzburg, Strubergasse 16, Salzburg, 5020, Austria.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Grabmer</LastName><ForeName>Christoph</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Department of Transfusion Medicine, University Hospital of Salzburg (SALK), Paracelsus Medical University (PMU) Salzburg, M&#xfc;llner-Hauptstra&#xdf;e 48, Salzburg, 5020, Austria.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Weidner</LastName><ForeName>Lisa</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Austrian Red Cross, Blood Service for Vienna, Lower Austria and Burgenland, Wiedner Hauptstra&#xdf;e 32, Vienna, 1040, Austria.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Jungbauer</LastName><ForeName>Christof</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Austrian Red Cross, Blood Service for Vienna, Lower Austria and Burgenland, Wiedner Hauptstra&#xdf;e 32, Vienna, 1040, Austria.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lindlbauer</LastName><ForeName>Nadja</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Department of Transfusion Medicine, University Hospital of Salzburg (SALK), Paracelsus Medical University (PMU) Salzburg, M&#xfc;llner-Hauptstra&#xdf;e 48, Salzburg, 5020, Austria.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Neureiter</LastName><ForeName>Heidrun</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Department of Transfusion Medicine, University Hospital of Salzburg (SALK), Paracelsus Medical University (PMU) Salzburg, M&#xfc;llner-Hauptstra&#xdf;e 48, Salzburg, 5020, Austria.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ortner</LastName><ForeName>Tuulia</ForeName><Initials>T</Initials><Identifier Source="ORCID">0000-0002-5703-6915</Identifier><AffiliationInfo><Affiliation>Department of Psychological Assessment, Institute of Psychology, Paris-Lodron-University of Salzburg, Salzburg, Austria.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Flamm</LastName><ForeName>Maria</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Institute of General Practice, Family Medicine and Preventive Medicine, PMU Salzburg, Strubergasse 21, Salzburg, 5020, Austria.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Osterbrink</LastName><ForeName>J&#xfc;rgen</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Institute of Nursing Science and Practice, PMU Salzburg, Strubergasse 21, Salzburg, 5020, Austria.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rohde</LastName><ForeName>Eva</ForeName><Initials>E</Initials><Identifier Source="ORCID">0000-0001-8692-886X</Identifier><AffiliationInfo><Affiliation>Department of Transfusion Medicine, University Hospital of Salzburg (SALK), Paracelsus Medical University (PMU) Salzburg, M&#xfc;llner-Hauptstra&#xdf;e 48, Salzburg, 5020, Austria.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Spinal Cord Injury and Tissue Regeneration Centre Salzburg, PMU Salzburg, Strubergasse 21, Salzburg, 5020, Austria.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Laner-Plamberger</LastName><ForeName>Sandra</ForeName><Initials>S</Initials><Identifier Source="ORCID">0000-0002-1416-6023</Identifier><AffiliationInfo><Affiliation>Department of Transfusion Medicine, University Hospital of Salzburg (SALK), Paracelsus Medical University (PMU) Salzburg, M&#xfc;llner-Hauptstra&#xdf;e 48, Salzburg, 5020, Austria. s.laner-plamberger@salk.at.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>20204-WISS/225/197-2019</GrantID><Agency>Salzburger Landesregierung (WISS 2025)</Agency><Country/></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2023</Year><Month>11</Month><Day>15</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>BMC Infect Dis</MedlineTA><NlmUniqueID>100968551</NlmUniqueID><ISSNLinking>1471-2334</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000956">Antigens, Viral</NameOfSubstance></Chemical><Chemical><RegistryNumber>670-65-5</RegistryNumber><NameOfSubstance UI="D019798">Neopterin</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000914">Antibodies, Viral</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D007075">Immunoglobulin M</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D007074">Immunoglobulin G</NameOfSubstance></Chemical><Chemical><RegistryNumber>9007-49-2</RegistryNumber><NameOfSubstance UI="D004247">DNA</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004854" MajorTopicYN="N">Herpesvirus 4, Human</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D020031" MajorTopicYN="Y">Epstein-Barr Virus Infections</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000086402" MajorTopicYN="N">SARS-CoV-2</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000956" MajorTopicYN="N">Antigens, Viral</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D019798" MajorTopicYN="N">Neopterin</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086382" MajorTopicYN="Y">COVID-19</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000914" MajorTopicYN="N">Antibodies, Viral</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007075" MajorTopicYN="N">Immunoglobulin M</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007074" MajorTopicYN="N">Immunoglobulin G</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004247" MajorTopicYN="N">DNA</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">COVID-19</Keyword><Keyword MajorTopicYN="N">EBV</Keyword><Keyword MajorTopicYN="N">Long-COVID</Keyword><Keyword MajorTopicYN="N">Post-COVID-19-syndrome (PCS)</Keyword><Keyword MajorTopicYN="N">SARS-CoV-2</Keyword></KeywordList><CoiStatement>The authors declare no competing interests. The authors declare to have no conflicts of interest and no competing interests.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2023</Year><Month>9</Month><Day>13</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2023</Year><Month>11</Month><Day>14</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>11</Month><Day>27</Day><Hour>12</Hour><Minute>43</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2023</Year><Month>11</Month><Day>16</Day><Hour>6</Hour><Minute>45</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2023</Year><Month>11</Month><Day>16</Day><Hour>0</Hour><Minute>14</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2023</Year><Month>11</Month><Day>15</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">37968601</ArticleId><ArticleId IdType="pmc">PMC10652630</ArticleId><ArticleId IdType="doi">10.1186/s12879-023-08820-w</ArticleId><ArticleId IdType="pii">10.1186/s12879-023-08820-w</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>WHO, Coronavirus disease (COVID-19). : Post COVID-19 condition, https://www.who.int/news-room/questions-and-answers/item/coronavirus-disease-(covid-19)-post-covid-19-condition (2021).</Citation></Reference><Reference><Citation>Zimmermann P, Pittet LF, Curtis N. The challenge of studying long COVID: an updated review. Pediatr Infect Dis J. 2022;41(5):424&#x2013;6. doi: 10.1097/INF.0000000000003502.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/INF.0000000000003502</ArticleId><ArticleId IdType="pmc">PMC8997013</ArticleId><ArticleId IdType="pubmed">35213866</ArticleId></ArticleIdList></Reference><Reference><Citation>Davis HE, McCorkell L, Vogel JM, Topol EJ. Long COVID: major findings, mechanisms and recommendations. Nat Rev Microbiol. 2023;21(3):133&#x2013;46. doi: 10.1038/s41579-022-00846-2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41579-022-00846-2</ArticleId><ArticleId IdType="pmc">PMC9839201</ArticleId><ArticleId IdType="pubmed">36639608</ArticleId></ArticleIdList></Reference><Reference><Citation>Thompson EJ, Williams DM, Walker AJ, Mitchell RE, Niedzwiedz CL, Yang TC, Huggins CF, Kwong ASF, Silverwood RJ, Di Gessa G, Bowyer RCE, Northstone K, Hou B, Green MJ, Dodgeon B, Doores KJ, Duncan EL, Williams FMK, Open SC, Steptoe A, Porteous DJ, McEachan RRC, Tomlinson L, Goldacre B, Patalay P, Ploubidis GB, Katikireddi SV, Tilling K, Rentsch CT, Timpson NJ, Chaturvedi N, Steves CJ. Long COVID burden and risk factors in 10 UK longitudinal studies and electronic health records. Nat Commun. 2022;13(1):3528. doi: 10.1038/s41467-022-30836-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41467-022-30836-0</ArticleId><ArticleId IdType="pmc">PMC9240035</ArticleId><ArticleId IdType="pubmed">35764621</ArticleId></ArticleIdList></Reference><Reference><Citation>Ballering AV, van Zon SKR, Olde Hartman TC, Rosmalen JGM. Lifelines Corona Research, persistence of somatic symptoms after COVID-19 in the Netherlands: an observational cohort study. Lancet. 2022;400(10350):452&#x2013;61. doi: 10.1016/S0140-6736(22)01214-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(22)01214-4</ArticleId><ArticleId IdType="pmc">PMC9352274</ArticleId><ArticleId IdType="pubmed">35934007</ArticleId></ArticleIdList></Reference><Reference><Citation>Fernandez-de-Las-Penas C, Cancela-Cilleruelo I, Rodriguez-Jimenez J, Gomez-Mayordomo V, Pellicer-Valero OJ, Martin-Guerrero JD, Hernandez-Barrera V, Arendt-Nielsen L, Torres-Macho J. Associated-Onset symptoms and Post-COVID-19 symptoms in hospitalized COVID-19 survivors infected with Wuhan, Alpha or Delta SARS-CoV-2 variant. Pathogens. 2022;11(7). 10.3390/pathogens11070725.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9320021</ArticleId><ArticleId IdType="pubmed">35889971</ArticleId></ArticleIdList></Reference><Reference><Citation>Antonelli M, Pujol JC, Spector TD, Ourselin S, Steves CJ. Risk of long COVID associated with delta versus omicron variants of SARS-CoV-2. Lancet. 2022;399(10343):2263&#x2013;4. doi: 10.1016/S0140-6736(22)00941-2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(22)00941-2</ArticleId><ArticleId IdType="pmc">PMC9212672</ArticleId><ArticleId IdType="pubmed">35717982</ArticleId></ArticleIdList></Reference><Reference><Citation>Nunhofer V, Hoeggerl AD, Weidner L, Zimmermann G, Badstuber N, Grabmer C, Jungbauer C, Lindlbauer N, Neureiter H, Held N, Ortner T, Flamm M, Osterbrink J, Rohde E, Laner-Plamberger S. Long-COVID Rates Vary throughout the SARS-CoV-2 pandemic. J Infect Dis Ther. 2023;11(01). 10.4172/2332-0877.1000520.</Citation></Reference><Reference><Citation>Al-Aly Z, Bowe B, Xie Y. Long COVID after breakthrough SARS-CoV-2 Infection. Nat Med. 2022;28(7):1461&#x2013;7. doi: 10.1038/s41591-022-01840-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41591-022-01840-0</ArticleId><ArticleId IdType="pmc">PMC9307472</ArticleId><ArticleId IdType="pubmed">35614233</ArticleId></ArticleIdList></Reference><Reference><Citation>Malkova A, Kudryavtsev I, Starshinova A, Kudlay D, Zinchenko Y, Glushkova A, Yablonskiy P, Shoenfeld Y. Post COVID-19 Syndrome in Patients with Asymptomatic/Mild Form, Pathogens. 2021;10(11). 10.3390/pathogens10111408.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8620929</ArticleId><ArticleId IdType="pubmed">34832564</ArticleId></ArticleIdList></Reference><Reference><Citation>O&#x2019;Mahoney LL, Routen A, Gillies C, Ekezie W, Welford A, Zhang A, Karamchandani U, Simms-Williams N, Cassambai S, Ardavani A, Wilkinson TJ, Hawthorne G, Curtis F, Kingsnorth AP, Almaqhawi A, Ward T, Ayoubkhani D, Banerjee A, Calvert M, Shafran R, Stephenson T, Sterne J, Ward H, Evans RA, Zaccardi F, Wright S, Khunti K. The prevalence and long-term health effects of long covid among hospitalised and non-hospitalised populations: a systematic review and meta-analysis. EClinicalMedicine. 2023;55:101762. doi: 10.1016/j.eclinm.2022.101762.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.eclinm.2022.101762</ArticleId><ArticleId IdType="pmc">PMC9714474</ArticleId><ArticleId IdType="pubmed">36474804</ArticleId></ArticleIdList></Reference><Reference><Citation>Taquet M, Dercon Q, Luciano S, Geddes JR, Husain M, Harrison PJ. Incidence, co-occurrence, and evolution of long-COVID features: a 6-month retrospective cohort study of 273,618 survivors of COVID-19. PLoS Med. 2021;18(9):e1003773. doi: 10.1371/journal.pmed.1003773.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pmed.1003773</ArticleId><ArticleId IdType="pmc">PMC8478214</ArticleId><ArticleId IdType="pubmed">34582441</ArticleId></ArticleIdList></Reference><Reference><Citation>Deer RR, Rock MA, Vasilevsky N, Carmody L, Rando H, Anzalone AJ, Basson MD, Bennett TD, Bergquist T, Boudreau EA, Bramante CT, Byrd JB, Callahan TJ, Chan LE, Chu H, Chute CG, Coleman BD, Davis HE, Gagnier J, Greene CS, Hillegass WB, Kavuluru R, Kimble WD, Koraishy FM, Kohler S, Liang C, Liu F, Liu H, Madhira V, Madlock-Brown CR, Matentzoglu N, Mazzotti DR, McMurry JA, McNair DS, Moffitt RA, Monteith TS, Parker AM, Perry MA, Pfaff E, Reese JT, Saltz J, Schuff RA, Solomonides AE, Solway J, Spratt H, Stein GS, Sule AA, Topaloglu U, Vavougios GD, Wang L, Haendel MA, Robinson PN. Characterizing Long COVID: Deep Phenotype of a Complex Condition, E Bio Medicine. 2021;74:103722. 10.1016/j.ebiom.2021.103722.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8613500</ArticleId><ArticleId IdType="pubmed">34839263</ArticleId></ArticleIdList></Reference><Reference><Citation>Subramanian A, Nirantharakumar K, Hughes S, Myles P, Williams T, Gokhale KM, Taverner T, Chandan JS, Brown K, Simms-Williams N, Shah AD, Singh M, Kidy F, Okoth K, Hotham R, Bashir N, Cockburn N, Lee SI, Turner GM, Gkoutos GV, Aiyegbusi OL, McMullan C, Denniston AK, Sapey E, Lord JM, Wraith DC, Leggett E, Iles C, Marshall T, Price MJ, Marwaha S, Davies EH, Jackson LJ, Matthews KL, Camaradou J, Calvert M, Haroon S. Symptoms and risk factors for long COVID in non-hospitalized adults. Nat Med. 2022;28(8):1706&#x2013;14. doi: 10.1038/s41591-022-01909-w.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41591-022-01909-w</ArticleId><ArticleId IdType="pmc">PMC9388369</ArticleId><ArticleId IdType="pubmed">35879616</ArticleId></ArticleIdList></Reference><Reference><Citation>Ramakrishnan RK, Kashour T, Hamid Q, Halwani R, Tleyjeh IM. Unraveling the mystery surrounding Post-acute Sequelae of COVID-19. Front Immunol. 2021;12:686029. doi: 10.3389/fimmu.2021.686029.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2021.686029</ArticleId><ArticleId IdType="pmc">PMC8278217</ArticleId><ArticleId IdType="pubmed">34276671</ArticleId></ArticleIdList></Reference><Reference><Citation>Mehandru S, Merad M. Pathological sequelae of long-haul COVID. Nat Immunol. 2022;23(2):194&#x2013;202. doi: 10.1038/s41590-021-01104-y.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41590-021-01104-y</ArticleId><ArticleId IdType="pmc">PMC9127978</ArticleId><ArticleId IdType="pubmed">35105985</ArticleId></ArticleIdList></Reference><Reference><Citation>Mantovani A, Morrone MC, Patrono C, Santoro MG, Schiaffino S, Remuzzi G, Bussolati G. Covid-19 Commission of the Accademia Nazionale dei, long covid: where we stand and challenges ahead. Cell Death Differ. 2022;29(10):1891&#x2013;900. doi: 10.1038/s41418-022-01052-6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41418-022-01052-6</ArticleId><ArticleId IdType="pmc">PMC9449925</ArticleId><ArticleId IdType="pubmed">36071155</ArticleId></ArticleIdList></Reference><Reference><Citation>Cohen JI. Epstein-Barr virus Infection. N Engl J Med. 2000;343(7). 10.1056/NEJM200008173430707. 481 &#x2013; 92.</Citation><ArticleIdList><ArticleId IdType="pubmed">10944566</ArticleId></ArticleIdList></Reference><Reference><Citation>Naendrup JH, Garcia Borrega J, Eichenauer DA, Shimabukuro-Vornhagen A, Kochanek M, Boll B. Reactivation of EBV and CMV in severe COVID-19-Epiphenomena or trigger of hyperinflammation in need of treatment? A large Case Series of critically ill patients. J Intensive Care Med. 2022;37(9):1152&#x2013;8. doi: 10.1177/08850666211053990.</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/08850666211053990</ArticleId><ArticleId IdType="pmc">PMC9396115</ArticleId><ArticleId IdType="pubmed">34791940</ArticleId></ArticleIdList></Reference><Reference><Citation>Paolucci S, Cassaniti I, Novazzi F, Fiorina L, Piralla A, Comolli G, Bruno R, Maserati R, Gulminetti R, Novati S, Mojoli F, Baldanti F. San Matteo Pavia, EBV DNA increase in COVID-19 patients with impaired lymphocyte subpopulation count. Int J Infect Dis. 2021;104:315&#x2013;9. doi: 10.1016/j.ijid.2020.12.051.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ijid.2020.12.051</ArticleId><ArticleId IdType="pmc">PMC7833117</ArticleId><ArticleId IdType="pubmed">33359064</ArticleId></ArticleIdList></Reference><Reference><Citation>Gold JE, Okyay RA, Licht WE, Hurley DJ. Investigation of long COVID prevalence and its relationship to Epstein-Barr Virus Reactivation. Pathogens. 2021;10(6). 10.3390/pathogens10060763.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8233978</ArticleId><ArticleId IdType="pubmed">34204243</ArticleId></ArticleIdList></Reference><Reference><Citation>Su Y, Yuan D, Chen DG, Ng RH, Wang K, Choi J, Li S, Hong S, Zhang R, Xie J, Kornilov SA, Scherler K, Pavlovitch-Bedzyk AJ, Dong S, Lausted C, Lee I, Fallen S, Dai CL, Baloni P, Smith B, Duvvuri VR, Anderson KG, Li J, Yang F, Duncombe CJ, McCulloch DJ, Rostomily C, Troisch P, Zhou J, Mackay S, DeGottardi Q, May DH, Taniguchi R, Gittelman RM, Klinger M, Snyder TM, Roper R, Wojciechowska G, Murray K, Edmark R, Evans S, Jones L, Zhou Y, Rowen L, Liu R, Chour W, Algren HA, Berrington WR, Wallick JA, Cochran RA, Micikas ME, Unit IS-SC-B, Wrin T, Petropoulos CJ, Cole HR, Fischer TD, Wei W, Hoon DSB, Price ND, Subramanian N, Hill JA, Hadlock J, Magis AT, Ribas A, Lanier LL, Boyd SD, Bluestone JA, Chu H, Hood L, Gottardo R, Greenberg PD, Davis MM, Goldman JD, Heath JR. Multiple early factors anticipate post-acute COVID-19 sequelae. Cell. 2022;185(5):881&#x2013;895e20. doi: 10.1016/j.cell.2022.01.014.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cell.2022.01.014</ArticleId><ArticleId IdType="pmc">PMC8786632</ArticleId><ArticleId IdType="pubmed">35216672</ArticleId></ArticleIdList></Reference><Reference><Citation>Eisenhut M. Neopterin in Diagnosis and Monitoring of Infectious Diseases, J Biomark. 2013;2013:196432. 10.1155/2013/196432.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4437389</ArticleId><ArticleId IdType="pubmed">26317013</ArticleId></ArticleIdList></Reference><Reference><Citation>Weidner L, Nunhofer V, Jungbauer C, Hoeggerl AD, Gruner L, Grabmer C, Zimmermann G, Rohde E, Laner-Plamberger S. Seroprevalence of anti-SARS-CoV-2 total antibody is higher in younger Austrian blood donors. Infection. 2021;49(6):1187&#x2013;94. doi: 10.1007/s15010-021-01639-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s15010-021-01639-0</ArticleId><ArticleId IdType="pmc">PMC8208066</ArticleId><ArticleId IdType="pubmed">34132990</ArticleId></ArticleIdList></Reference><Reference><Citation>Nunhofer V, Weidner L, Hoeggerl AD, Zimmermann G, Badstuber N, Grabmer C, Jungbauer C, Lindlbauer N, Held N, Pascariuc M, Ortner T, Rohde E. Laner-Plamberger, persistence of naturally acquired and functional SARS-CoV-2 antibodies in blood donors one year after Infection. Viruses. 2022;14(3). 10.3390/v14030637.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8953712</ArticleId><ArticleId IdType="pubmed">35337044</ArticleId></ArticleIdList></Reference><Reference><Citation>Hess RD. Routine Epstein-Barr virus diagnostics from the laboratory perspective: still challenging after 35 years. J Clin Microbiol. 2004;42(8):3381&#x2013;7. doi: 10.1128/JCM.42.8.3381-3387.2004.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/JCM.42.8.3381-3387.2004</ArticleId><ArticleId IdType="pmc">PMC497621</ArticleId><ArticleId IdType="pubmed">15297472</ArticleId></ArticleIdList></Reference><Reference><Citation>De Paschale M, Clerici P. Serological diagnosis of Epstein-Barr virus Infection: problems and solutions. World J Virol. 2012;1(1):31&#x2013;43. doi: 10.5501/wjv.v1.i1.31.</Citation><ArticleIdList><ArticleId IdType="doi">10.5501/wjv.v1.i1.31</ArticleId><ArticleId IdType="pmc">PMC3782265</ArticleId><ArticleId IdType="pubmed">24175209</ArticleId></ArticleIdList></Reference><Reference><Citation>AbuSalah MAH, Gan SH, Al-Hatamleh MAI, Irekeola AA, Shueb RH. Yean Yean, recent advances in Diagnostic approaches for Epstein-Barr Virus. Pathogens. 2020;9(3). 10.3390/pathogens9030226.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7157745</ArticleId><ArticleId IdType="pubmed">32197545</ArticleId></ArticleIdList></Reference><Reference><Citation>Bu W, Hayes GM, Liu H, Gemmell L, Schmeling DO, Radecki P, Aguilar F, Burbelo PD, Woo J, Balfour HH, Jr, Cohen JI. Kinetics of Epstein-Barr Virus (EBV) Neutralizing and Virus-Specific Antibodies after primary Infection with EBV. Clin Vaccine Immunol. 2016;23(4):363&#x2013;9. doi: 10.1128/CVI.00674-15.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/CVI.00674-15</ArticleId><ArticleId IdType="pmc">PMC4820504</ArticleId><ArticleId IdType="pubmed">26888186</ArticleId></ArticleIdList></Reference><Reference><Citation>Noguchi K, Gel YR, Brunner E, Konietschke F. nparLD: an R Software Package for the Nonparametric Analysis of Longitudinal Data in Factorial experiments. J Stat Softw. 2012;50(12):1&#x2013;23. doi: 10.18637/jss.v050.i12.</Citation><ArticleIdList><ArticleId IdType="doi">10.18637/jss.v050.i12</ArticleId><ArticleId IdType="pubmed">0</ArticleId></ArticleIdList></Reference><Reference><Citation>R-Core-Team. A language and environment for statistical computing. R Foundation for Statistical Computing, Vienna, Austria., in: R-Core-Team, editor R-Core-Team, 2022.</Citation></Reference><Reference><Citation>Mayersbach P, Fuchs D, Schennach H. Performance of a fully automated quantitative neopterin measurement assay in a routine voluntary blood donation setting. Clin Chem Lab Med. 2010;48(3):373&#x2013;7. doi: 10.1515/CCLM.2010.072.</Citation><ArticleIdList><ArticleId IdType="doi">10.1515/CCLM.2010.072</ArticleId><ArticleId IdType="pubmed">20020818</ArticleId></ArticleIdList></Reference><Reference><Citation>Robertson J, Gostner JM, Nilsson S, Andersson LM, Fuchs D, Gisslen M. Serum neopterin levels in relation to mild and severe COVID-19. BMC Infect Dis. 2020;20(1):942. doi: 10.1186/s12879-020-05671-7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12879-020-05671-7</ArticleId><ArticleId IdType="pmc">PMC7726600</ArticleId><ArticleId IdType="pubmed">33302893</ArticleId></ArticleIdList></Reference><Reference><Citation>Bellmann-Weiler R, Lanser L, Burkert F, Seiwald S, Fritsche G, Wildner S, Schroll A, Koppelstatter S, Kurz K, Griesmacher A, Weiss G. Neopterin predicts Disease Severity in hospitalized patients with COVID-19. Open Forum Infect Dis. 2021;8(1):ofaa521. doi: 10.1093/ofid/ofaa521.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/ofid/ofaa521</ArticleId><ArticleId IdType="pmc">PMC7665702</ArticleId><ArticleId IdType="pubmed">33442554</ArticleId></ArticleIdList></Reference><Reference><Citation>Nagata K, Hayashi K. Epstein-Barr Virus Reactivation-Induced Immunoglobulin production: significance on autoimmunity. Microorganisms. 2020;8(12). 10.3390/microorganisms8121875.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7760294</ArticleId><ArticleId IdType="pubmed">33260824</ArticleId></ArticleIdList></Reference><Reference><Citation>Nunn AVW, Guy GW, Brysch W, Botchway SW, Frasch W, Calabrese EJ, Bell JD. SARS-CoV-2 and mitochondrial health: implications of lifestyle and ageing. Immun Ageing. 2020;17(1):33. doi: 10.1186/s12979-020-00204-x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12979-020-00204-x</ArticleId><ArticleId IdType="pmc">PMC7649575</ArticleId><ArticleId IdType="pubmed">33292333</ArticleId></ArticleIdList></Reference><Reference><Citation>Yang Y, Yang M, Peng Y, Liang Y, Wei J, Xing L, Guo L, Li X, Li J, Wang J, Li M, Xu Z, Zhang M, Wang F, Shi Y, Yuan J, Liu Y. Longitudinal analysis of antibody dynamics in COVID-19 convalescents reveals neutralizing responses up to 16 months after Infection. Nat Microbiol. 2022;7(3):423&#x2013;33. doi: 10.1038/s41564-021-01051-2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41564-021-01051-2</ArticleId><ArticleId IdType="pubmed">35132197</ArticleId></ArticleIdList></Reference><Reference><Citation>Peluso MJ, Deveau TM, Munter SE, Ryder D, Buck A, Beck-Engeser G, Chan F, Lu S, Goldberg SA, Hoh R, Tai V, Torres L, Iyer NS, Deswal M, Ngo LH, Buitrago M, Rodriguez A, Chen JY, Yee BC, Chenna A, Winslow JW, Petropoulos CJ, Deitchman AN, Hellmuth J, Spinelli MA, Durstenfeld MS, Hsue PY, Kelly JD, Martin JN, Deeks SG, Hunt PW, Henrich TJ. Chronic viral coinfections differentially affect the likelihood of developing long COVID. J Clin Invest. 2023;133(3). 10.1172/JCI163669.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9888380</ArticleId><ArticleId IdType="pubmed">36454631</ArticleId></ArticleIdList></Reference><Reference><Citation>Maurmann S, Fricke L, Wagner HJ, Schlenke P, Hennig H, Steinhoff J, Jabs WJ. Molecular parameters for precise diagnosis of asymptomatic Epstein-Barr virus reactivation in healthy carriers. J Clin Microbiol. 2003;41(12):5419&#x2013;28. doi: 10.1128/JCM.41.12.5419-5428.2003.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/JCM.41.12.5419-5428.2003</ArticleId><ArticleId IdType="pmc">PMC308959</ArticleId><ArticleId IdType="pubmed">14662920</ArticleId></ArticleIdList></Reference><Reference><Citation>Davis HE, Assaf GS, McCorkell L, Wei H, Low RJ, Re&#x2019;em Y, Redfield S, Austin JP, Akrami A. Characterizing long COVID in an international cohort: 7 months of symptoms and their impact. EClinicalMedicine. 2021;38:101019. doi: 10.1016/j.eclinm.2021.101019.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.eclinm.2021.101019</ArticleId><ArticleId IdType="pmc">PMC8280690</ArticleId><ArticleId IdType="pubmed">34308300</ArticleId></ArticleIdList></Reference><Reference><Citation>Ziauddeen N, Gurdasani D, O&#x2019;Hara ME, Hastie C, Roderick P, Yao G, Alwan NA. Characteristics and impact of Long Covid: findings from an online survey. PLoS ONE. 2022;17(3):e0264331. doi: 10.1371/journal.pone.0264331.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0264331</ArticleId><ArticleId IdType="pmc">PMC8903286</ArticleId><ArticleId IdType="pubmed">35259179</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>